Artelo Biosciences (NASDAQ:ARTL) Posts Earnings Results

Artelo Biosciences (NASDAQ:ARTL) posted its quarterly earnings data on Tuesday. The company reported ($0.04) earnings per share (EPS) for the quarter, FiscalAI reports.

Artelo Biosciences Price Performance

ARTL opened at $1.24 on Tuesday. The stock’s 50 day simple moving average is $1.50 and its 200 day simple moving average is $3.54. The firm has a market cap of $2.50 million, a price-to-earnings ratio of -0.06 and a beta of 1.12. Artelo Biosciences has a 1 year low of $1.10 and a 1 year high of $28.60.

Analyst Ratings Changes

Several equities research analysts have issued reports on ARTL shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Artelo Biosciences in a research note on Monday, December 29th. Maxim Group reaffirmed a “hold” rating on shares of Artelo Biosciences in a research note on Wednesday, November 19th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $24.00.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.